SCHEMBL29212

SCHEMBL29212

O[C@@H]1[CH]OC[C@H]1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29571 1.00
SCHEMBL3516924 1.00
SCHEMBL371416 1.00
SCHEMBL28669 0.82
SCHEMBL28771 0.82
SCHEMBL29450 0.82
SCHEMBL1501859 0.82
SCHEMBL29413 0.82
SCHEMBL29288 0.82
SCHEMBL1133698 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 516 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024126654-A1 ANTISENSE OLIGONUCLEOTIDES TARGETING ACTL6B F. HOFFMANN-LA ROCHE AG (CH) 2024-06-20 WO claimed
WO-2024046937-A1 THREOSE NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDES AND METHODS THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2024-03-07 WO claimed
WO-2023175091-A2 MAPT siRNA AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2023-09-21 WO claimed
WO-2023117738-A1 THREOSE NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDES AND METHODS THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2023-06-29 WO claimed
WO-2020101880-A1 COMPOSITIONS AND METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 2020-05-22 WO claimed
US-7465734-B2 Methods and compositions for overcoming resistance to biologic and chemotherapy CELMED ONCOLOGY (USA), INC. (CA) 2008-12-16 US claimed
WO-2008022469-A1 2'-DEOXY-2'-FLUORO-β-D-ARABINONUCLEOSIDE 5'-TRIPHOSPHATES AND THEIR USE IN ENZYMATIC NUCLEIC ACID SYNTHESIS MCGILL UNIVERSITY (CA) 2008-02-28 WO claimed
CN-118339293-A 5' -UTR with improved translational efficiency, synthetic nucleic acid molecules comprising same, and vaccine or therapeutic composition comprising same 财团法人牧岩生命科学研究所 2024-07-12 CN disclosed
EP-4363572-A1 METHOD FOR SYNTHESIS OF LINKAGE MODIFIED OLIGOMERIC COMPOUNDS Ionis Pharmaceuticals, Inc. (US) 2024-05-08 EP disclosed
WO-2024073732-A1 MODIFIED DOUBLE-STRANDED RNA AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2024-04-04 WO disclosed
WO-2024064803-A2 TENSION-ACTIVATED CELL TAGGING (TACT) EMORY UNIVERSITY (US) 2024-03-28 WO disclosed
WO-2024052379-A1 THERAPEUTIC AGENTS FOR METABOLISM-ASSOCIATED DISEASES UNITED KINGDOM RESEARCH AND INNOVATION (GB) 2024-03-14 WO disclosed
WO-2024046937-A1 THREOSE NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDES AND METHODS THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2024-03-07 WO disclosed
WO-1999008110-A1 METHODS AND COMPOSITIONS FOR OVERCOMING RESISTANCE TO BIOLOGIC AND CHEMOTHERAPY NEWBIOTICS, INC. (US) 1999-02-18 WO disclosed
WO-1999006424-A1 LYXOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1999-02-11 WO disclosed
US-5840743-A TREATING HERPES VIRUS, CYTOMEGALO VIRUS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1998-11-24 US disclosed
WO-1998040390-A2 OLIGOSACCHARIDES AND THE DERIVATIVES THEREOF, CHEMO-ENZYMATIC METHOD FOR THE PRODUCTION THEREOF BAYER AKTIENGESELLSCHAFT (DE) 1998-09-17 WO disclosed
EP-0832898-A2 Substituted amino acid derivatives BAYER AG (DE) 1998-04-01 EP disclosed
WO-1997027204-A1 MODIFIED BENZIMIDAZOLE NUCLEOSIDES AS ANTIVIRAL AGENTS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1997-07-31 WO disclosed
WO-1997027205-A1 IMIDAZO[1,2-A]PYRIDINE C-NUCLEOSIDES AS ANTIVIRAL AGENTS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1997-07-31 WO disclosed